Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3,4-Diarylpyrazolines as Potent and Selective CB1 Cannabinoid Receptor Antagonists

Journal of Medicinal Chemistry

Volumn 47, Issue 3, 2004, Pages 627-643

  Lange, Jos H M ^a   Coolen, Hein K A C ^a   Van Stuivenberg, Herman H ^a   Dijksman, Jessica A R ^a   Herremans, Arnoud H J ^a   Ronken, Eric ^a   Keizer, Hiskias G ^a   Tipker, Koos ^a   McCreary, Andrew C ^a   Veerman, Willem ^a   Wals, Henri C ^a   Stork, Bob ^a   Verveer, Peter C ^a   Den Hartog, Arnold P ^a   De Jong, Natasja M J ^a   Adolfs, Tiny J P ^a   Hoogendoorn, Jan ^a   Kruse, Chris G ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 CHLOROPHENYL) N [(4 METHYLPHENYL)SULFONYL] 4 PHENYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; 3 (4 CHLOROPHENYL) N METHYL N' [(4 CHLOROPHENYL)SULFONYL] 4 PHENYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDE; AMIDINE; AMINE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; METHYLAMINE; PYRAZOLINE DERIVATIVE; RECEPTOR BLOCKING AGENT; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIRALITY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; HYPOTENSION; HYPOTHERMIA; MALE; MOLECULAR MODEL; NONHUMAN; RACEMIC MIXTURE; RAT; REACTION ANALYSIS; STRUCTURE ANALYSIS; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; ARACHIDONIC ACID; BINDING, COMPETITIVE; BIOLOGICAL AVAILABILITY; CHO CELLS; CRICETINAE; CRYSTALLOGRAPHY, X-RAY; FEVER; HUMANS; HYPOTENSION; MALE; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PYRAZOLES; RADIOLIGAND ASSAY; RATS; RECEPTOR, CANNABINOID, CB1; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 9144260517     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031019q     Document Type: Article

References (43)

1. Robson, P. Therapeutic aspects of cannabis and cannabinoids. Br. J. Psychiatry 2001, 178, 107-115.
2. Croxford, J. L. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003, 17, 179-202.
3. Glass, M. The role of cannabinoids in neurodegenerative diseases. Progr. Neuro-Psychopharmacol., Biol. Psychiat. 2001, 25, 743-765.
4. Consroe, P. Brain cannabinoid systems as targets fore the therapy of neurological disorders. Neurobiol. Dis. 1998, 5, 534-551.
5. Matsuda, L. A.; Lolait, S. J.; Brownstein, B. J.; Young, A. C.; Bonner. T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 356, 561-564.
6. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365, 61-62.
7. Wilson, R.; Nicoll, R. A. Endocannabinoid signaling in the brain. Science 2002, 296, 678-682.
8. Breivogel, C. S.; Griffin, G.; Di Marzo, V.; Martin, B. R. Evidence for a new G protein-Coupled Cannabinoid receptor in mouse brain. Mol. Pharmacol. 2001, 60, 155-163.
9. Adam, J.; Cowley, P. Recent advances in the cannabinoids. Expert Opin. Ther. Pat. 2002, 12, 1475-1489.
10. Pertwee, R. G. Neuropharmacology and therapeutic potential of cannabinoids. Addict. Biol. 2000, 5, 37-46.
11. Gomez, R.; Navarro, M.; Ferrer, B.; Trigo, J. M.; Bilbao, A.; Del Arco, I.; Cippitelli, A.; Nava, F.; Piomelli, D.; De Fonseca, F. R. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J. Neurosci. 2002, 22, 9612-9617.
12. Hall, W. Cannabis and psychosis. Drug Alcohol Rev. 1998, 17, 433-444.
13. Hungund, B. L.; Basavarajappa, B. S.; Vadasz, C.; Kunos, G.; de Fonseca, F. R.; Colombo, G.; Serra, S.; Parsons, L.; Koob, G. F. Ethanol, endocannabinoids, and the cannabinoidergic signaling system. Alcohol Clin. Exp. Res. 2002, 26, 565-574.
14. Pertwee, R. G. Cannabinoids and the gastrointestinal tract. Gut 2001, 48, 859-867.
15. Lan, R.; Liu, Q.; Fan, P.; Lin, S.; Fernando, S. R.; McCallion, D.; Pertwee, R.; Makriyannis, A. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. 1999, 42, 769-776.
16. Grosscurt, A. C.; Van Hes, R.; Wellinga, K. 1-Phenylcarbamoyl-2-pyrazolines, a new class of insecticides. 3. Synthesis and insecticidal properties of 3,4-diphenyl-1-phenylcarbamoyl-2-pyrazolines. J. Agric. Food Chem. 1979, 27, 406-409.
17. Gompper, R.; Hägele, W. N-Sulfonyl-iminodithiokohlensäureester und N-Sulfonyl-dithiourethane. Chem. Ber. 1966, 99, 2885-2899.
18. Cho, N. S.; Shon, H. I. Synthesis of 5-(aroylamino)-2-methyl-2H-1,2,4-thiadiazol-3-ones by oxidative cyclisation of 1-aroyl-5-methyl-2-thiobiurets. J. Heterocycl. Chem. 1991, 28, 1645-1649.
19. Gerard, C. M.; Mollereau, C.; Vassart, G.; Parmentier, M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J. 1991, 279, 129-134.
20. Showalter, V. M.; Compton, D. R.; Martin, B. R.; Abood, M. E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 1996, 278, 989-999.
21. Bayewitch, M.; Rhee, R. H.; Avidorreis, T.; Breuer, A.; Mechoulam, R.; Vogel, Z. (-)-Delta(9)-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J. Biol. Chem. 1996, 271, 9902-9905.
22. Wagner, J. A.; Jarai, Z.; Batkai, S.; Kunos, G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors. Eur. J. Pharmacol. 2001, 423, 203-210.
23. Rawls, S. M.; Cabassa, J.; Geller, E. B.; Adler, M. W. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55,212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl) -6H-pyrrolo[3,2,ijlquinolin-6-one]-induced hypothermia. J. Pharmacol. Exp. Ther. 2002, 301, 963-968.
24. 1 cannabinoid receptor. J. Med. Chem. 2002, 45, 1447-1459.
25. Hurst, D. P.; Lynch, D. L.; Barnett-Norris, J.; Hyatt, S. M.; Seltzman, H. H.; Zhong, M.; Song, Z.-H.; Nie, J.; Lewis, D.; Reggio, P. R. N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methyl-1H-pyrazole-3-carboxamide (SR141716A) Interaction with LYS 3.28(192) is crucial for its inverse agonism at the Cannabinoid CB1 receptor. Mol. Pharmacol. 2002, 62, 1274-1287.
26. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H. B. A.; Fox, B. A.; LeTron, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E. Crystal structure of Rhodopsin: a G-protein-coupled receptor. Science 2000, 289, 739-745.
27. Barnet-Norris, J.; Hurst, D. P.; Buehner, K.; Ballesteros, J. A.; Guarnieri, F.; Reggio P. H. Agonist alkyl tail interaction with Cannabinoid CB1 receptor V6.43/I6.46 groove induces a Helix 6 active conformation. Int. J. Quantum. Chem. 2002, 88, 76-86.
28. 2 adrenergic receptor mapped by site-selective Fluorescent Labeling. J. Biol. Chem. 2001, 276, 9279-9290.
29. Klebe, G.; Böhm, H.-J. Energetic and entropic factors determining binding affinity in protein-ligand complexes. J. Receptor Signal Transduct. Res. 1997, 17, 459-473.
30. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
31. Schinkel, A. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A. A. M.; Borst, P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J. Clin. Invest. 1995, 96, 1698-1705.
32. Palm; K.; Stenberg, P.; Luthman, K.; Artursson, P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 1997, 14, 568-571.
33. Kelder, J.; Grootenhuis, P. D. J.; Bayada, D. M.; Delbressine, L. P. C.; Ploemen, J.-P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 1999, 16, 1514-1519.
34. Van de Waterbeemd, H.; Jones, B. C. Predicting oral absorption and bioavailability. In Progress in Medicinal Chemistry; King, F. D.; Oxford, A. W., Eds.; Elsevier Science B. V.: Amsterdam, 2003; Vol. 41, pp 1-59.
35. Halbert, G. W. Pharmaceutical Development. In The Textbook of Pharmaceutical Medicine, 3rd ed.; Griffin, J. P., O'Grady, J., D'Arcy, P. F., Eds.; The Queen's University of Belfast: Belfast, 1998; pp 33-35.
36. Yalkowsky, S. H.; Valvani, S. C.; Solubility and partitioning. I. Solubility of nonelectrolytes in water. J. Pharm. Sci. 1980, 69, 912-922.
37. Jain, N.; Yalkowsky, S. H.; Estimation of the aqueous solubility I. Application to organic nonelectrolytes. J. Pharm. Sci. 2001, 90, 234-252.
38. Franz, J. E.; Osuch, C. The reactions of sulfonamides with oxalyl chloride. J. Org. Chem. 1964, 29, 2592-2595.
39. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
40. Reggio, P. H.; Basu-Dutt, S.; Barnett-Norris, J.; Castro, M. T.; Hurst, D. P.; Seltzman, H. H.; Roche, M. J.; Gilliam, A. F.; Thomas, B. F.; Stevenson, L. A.; Pertwee, R. G.; Abood, M. E. The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: Insights gained from (E)- and (Z)-naphylidene indenes J. Med. Chem. 1998, 41, 5177-5187.
41. OECD Guideline for Testing of Chemicals no. 117, adopted at 30-03-1989.
42. Tripos Inc., St. Louis, MO 63144.
43. Thompson, J. D.; Gibson, T. J.; Plewniak, F.; Jeanmougin, F.; Higgins, D. G. The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1997, 24, 4876-4882.